CymaBay's gout drug meets main goal in mid-stage study

February 24, 2015 11:26 AM

12 0

The company said its once-a-day drug, arhalofenate, was shown to be safe and well tolerated.

Gout is a condition affecting joints and muscles when the body acts against a build-up of uric acid in the blood.

Also read: FDA OKs 2nd gene therapy for blood cancer; 1st for adults

Read more

To category page